Aspira Women’s Health (AWHL) files 8-K with Q3 2025 results PR

Aspira Women’s Health Inc. filed a Form 8-K announcing it issued a press release reporting financial results for the three and nine months ended September 30, 2025.

Accepted by SEC EDGAR 11/14/2025 - 08:54 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aspira Women’s Health Inc. filed a Form 8-K announcing it issued a press release reporting financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.

The filing lists the company’s common stock trading on the OTC QX Market under the symbol AWHL.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AWHL disclose in this Form 8-K?

The company announced it issued a press release with financial results for the three and nine months ended September 30, 2025.

Which period do the results cover for AWHL?

They cover the three and nine months ended September 30, 2025.

Where can I find the detailed results for AWHL?

Details are in the press release attached as Exhibit 99.1.

What exhibit accompanies the AWHL 8-K?

Exhibit 99.1: the press release issued on November 14, 2025.

What is AWHL’s trading market and symbol?

Common stock trades on the OTC QX Market under the symbol AWHL.

Who signed the AWHL filing?

It was signed by Michael Buhle, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Aspira Women's Health Inc.0000926617false00009266172025-11-142025-11-14

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 14, 2025

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-34810		33-0595156
(State or other jurisdiction of	​	(Commission	​	(IRS Employer
incorporation or organization)	​	File Number)	​	Identification No.)

​

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001	​	AWHL	​	OTC QX Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 2.02 Results of Operations and Financial Conditions.

​

On November 14, 2025, Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and nine months ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

​

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

​	​	​
Exhibit No.		Description
99.1	​	Press Release issued by Aspira Women’s Health Inc. on November 14, 2025
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 14, 2025

​

	ASPIRA WOMEN’S HEALTH INC.
	By:	/s/ Michael Buhle
	Name:	Michael Buhle
	Title:	Chief Executive Officer

​

​

​